> In the journal PLOS ONE, D-Pharm published promising results from a study of its drug candidate DP-b99 suggesting that it may prevent lasting alterations in neuronal function and pathological brain reorganization--a hallmark of numerous central nervous system (CNS) diseases. Release
> Dutch antibody specialist arGEN-X has entered into a partnership with The Leukemia & Lymphoma Society to advance the company's lead candidate, ARGX-110, in patients with refractory Waldenström's macroglobulinemia. Release (PDF)
> Scientists from the University of Manchester have identified an important trigger that decides how embryonic stem cells differentiate and gain specialized functions, a finding that could help researchers understand how cells can be artificially manipulated. Abstract